Results 141 to 150 of about 36,146 (282)

Off-Label Use of Bevacizumab in Patients Diagnosed with Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis

open access: yesPharmaceuticals
Background: Age-related macular degeneration (AMD) is the leading cause of vision loss in elderly people. Current pharmacological treatment in vascular AMD includes anti-VEGF agents, such as ranibizumab and aflibercept. Additionally, the off-label use of
João Estarreja   +4 more
doaj   +1 more source

Impact of COVID-19 on a real-world treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration [PDF]

open access: hybrid
Keean Nanji   +7 more
openalex   +1 more source

Effects of photodynamic therapy on subfoveal blood flow in neovascular age-related macular degeneration patients [PDF]

open access: bronze, 2009
V. Vinh Moreau-Gaudry   +5 more
openalex   +1 more source

Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open-label study [PDF]

open access: hybrid, 2023
Daniel S. Pereira   +6 more
openalex   +1 more source

Ocular syphilis masquerading as refractory retinal diseases

open access: yesBMC Infectious Diseases
Purpose To report two cases of syphilis masquerading as chronic refractory macular diseases. Case descriptions Two patients had been diagnosed with neovascular age-related macular degeneration (neovascular AMD) and diabetic macular edema (DME ...
Sung Who Park   +5 more
doaj   +1 more source

Comprehensive Analysis of CRP, CFH Y402H and Environmental Risk Factors on Risk of Neovascular Age-Related Macular Degeneration [PDF]

open access: yes, 2011
Purpose: To examine if the gene encoding C-reactive protein (CRP), a biomarker of inflammation, confers risk for neovascular age-related macular degeneration (AMD) in the presence of other modifiers of inflammation, including body mass index (BMI ...
Adams, Scott   +10 more
core  

Home - About - Disclaimer - Privacy